United Therapeutics Corp

United Therapeutics updates at JHC: focus on prostacyclin PAH therapies, value‑based contracts, patent strategy, and potential M&A for growth.

United Therapeutics Corporation reported record third-quarter 2025 results, exceeding Wall Street expectations with earnings per share of $7.16 and revenue of $799 million, driven by growth in its core product portfolio and strong operating cash flo…

United Therapeutics’ stock has seen a notable 11.9% gain since its last earnings report, driven by the company’s growing financial performance and investor confidence.

United Therapeutics and MannKind have expanded their partnership, leading to increased R&D efforts, improved product pipelines, and enhanced market presence in the pharmaceutical industry.

United Therapeutics has reported strong quarterly earnings, with a stock price of $313.22 and impressive price-to-earnings and price-to-book ratios, sparking interest among investors and analysts.

United Therapeutics has released its quarterly earnings report, highlighting fluctuations in its stock price and key financial metrics such as a price-to-earnings ratio of 12.22.

The company’s annual meeting and board meeting have led to significant developments, including a new vaccine production and a major aircraft order.

United Therapeutics’ quarterly earnings report showed revenue growth, but the company fell short of analyst expectations, leading to a decline in its stock price.

United Therapeutics Corporation reported an 11.71% revenue increase in its quarterly earnings, but missed earnings and revenue estimates, leading to a decline in its stock price.

United Therapeutics’ stock price has shown a notable uptrend, driven by the company’s stable foundation and moderate valuation metrics.